Evidence map›Paper›PMID 42846119›Full record

Trial reportTransplant international : official journal of the European Society for Organ Transplantation2026

Bortezomib in combination with standard-of-care for late active antibody-mediated rejection with de novo donor-specific antibodies after kidney transplantation: a multicenter randomized trial.

Renaud Snanoudj, Fabienne Marquant, Karine Renaudin, Valérie Dubois, Alice Koenig, Nadia Arzouk, Sophie Caillard, Magali Giral, Arwa Jalal Eddine, Hakim Mazouz and 6 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Transplant international : official journal of the European Society for Organ Transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Renaud SnanoudjNephrology Dialysis and Transplantation Department, Hopital Bicetre, Le Kremlin-Bicêtre, France.
Fabienne MarquantUnit of Clinical Research, Hopital Universitaire Necker-Enfants Malades, Paris, France.
Karine RenaudinPathology Department, Centre Hospitalier Universitaire de Nantes, Nantes, France.
Valérie DuboisHistocompatibility Department, Etablissement Francais du Sang Auvergne-Rhone-Alpes, Décines-Charpieu, France.
Alice KoenigTransplantation Department, Hospices Civils de Lyon, Lyon, France.
Nadia ArzoukTransplantation Department, Hopital Universitaire Pitie-Salpetriere, Paris, France.
Sophie CaillardNephrology Dialysis and Transplantation Department, Hopital Civil, Strasbourg, France.
Magali GiralNephrology Dialysis and Transplantation Department, Hotel Dieu, Nantes, France.
Arwa Jalal EddineNephrology Department, Hopital Foch, Suresnes, France.
Hakim MazouzNephrology and Transplantation Department, Centre Hospitalier Universitaire Amiens-Picardie, Amiens, France.
Nassim KamarNephrology and Organ Transplantation Department, Hopital de Rangueil, Toulouse, France.
Vincent PerninNephrology and Organ Transplantation Department, Hopital Lapeyronie, Montpellier, France.
Marie MatignonNephrology and Organ Transplantation Department, Hopitaux Universitaires Henri Mondor, Créteil, France.
Nacera OualiNephrology and Organ Transplantation Department, Hopital Tenon, Paris, France.
Dany AnglicheauDepartment of Kidney and Metabolic Diseases, Transplantation and Clinical Immunology, AP-HP, Necker Hospital, Université Paris Cité, Paris, France.
Caroline ElieUnit of Clinical Research, Hopital Universitaire Necker-Enfants Malades, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bortezomib has been proposed as a treatment for antibody-mediated rejection (AMR) after kidney transplantation; however, its efficacy remains uncertain. We conducted a multicenter, randomized, open-label trial in France between February 2015 and July 2019 in adult kidney transplant recipients with late active AMR associated with

Indexed as

BortezomibGraft RejectionImmunosuppressive AgentsKidney TransplantationAdrenal Cortex HormonesAdultAgedFemaleFranceHumansImmunoglobulins, IntravenousIsoantibodiesMaleMiddle AgedPlasmapheresisStandard of CareAdrenal Cortex HormonesBortezomibImmunoglobulins, IntravenousImmunosuppressive AgentsIsoantibodiesantibody-mediated rejectionbortezomibdonor-specific antibodiesimmunosuppressionkidney transplantation

Identifiers

PMID42846119
PMCPMC13642227

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.